Update on the urotensinergic system: New trends in receptor localization, activation, and drug design

Frontiers in Endocrinology

Volumn 3, Issue JAN, 2013, Pages

  Chatenet, David ^a,b   Nguyen, Thi Tuyet M ^a,b   Létourneau, Myriam ^a,b   Fournier, Alain ^a,b  

^a INRS INSTITUT ARMAND FRAPPIER   (Canada)

^b UNIVERSITÉ DE ROUEN   (France)

Author keywords

Allosteric modulation; Biased agonist; Nuclear receptors; Urotensin II; Urotensin II related peptide

Indexed keywords

EID: 84874269735     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00174     Document Type: Review

References (98)

1. Ames, R. S., Sarau, H. M., Chambers, J. K., Willette, R. N., Aiyar, N. V., Romanic, A. M., et al. (1999). Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401, 282-286.
2. Andreev, O. A., Karabadzhak, A. G., Weerakkody, D., Andreev, G. O., Engelman, D. M., and Reshetnyak, Y. K. (2010). pH (low) insertion peptide (pHLIP) inserts across a lipid bilayer as a helix and exits by a different path. Proc. Natl. Acad. Sci. U.S.A. 107,4081-4086.
3. Arantes, L. A., Aguiar, C. J., Amaya, M. J., Figueiro, N. C., Andrade, L. M., Rocha-Resende, C., et al. (2012). Nuclear inositol 1, 4, 5-trisphosphate is a necessary and conserved signal for the induction of both pathological and physiological cardiomyocyte hypertrophy. J. Mol. Cell. Cardiol. 53, 475-486.
4. Behm, D. J., Aiyar, N. V., Olzinski, A. R., McAtee, J. J., Hilfiker, M. A., Dodson, J. W., et al. (2010). GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharma-codynamic activity ex vivo. Br. J. Pharmacol. 161, 207-228.
5. Behm, D. J., McAtee, J. J., Dodson, J. W., Neeb, M. J., Fries, H. E., Evans, C. A., et al. (2008). Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues. Br. J. Pharmacol. 155, 374-386.
6. Bignami, A., Asher, R., and Perides, G. (1991). Brain extracellular matrix and nerve regeneration. Adv. Exp. Med. Biol. 296, 197-206.
7. Boivin, B., Chevalier, D., Villeneuve, L. R., Rousseau, E., and Allen, B. G. (2003). Functional endothelin receptors are present on nuclei in cardiac ventricular myocytes. J. Biol. Chem. 278, 29153-29163.
8. Boivin, B., Lavoie, C., Vaniotis, G., Baragli, A., Villeneuve, L. R., Ethier, N., et al. (2006). Functional beta-adrenergic receptor signalling on nuclear membranes in adult rat and mouse ventricular car-diomyocytes. Cardiovasc. Res. 71, 69-78.
9. Boivin, B., Vaniotis, G., Allen, B. G., and Hebert, T. E. (2008). G protein-coupled receptors in and on the cell nucleus: a new signaling paradigm? J. Recept. Signal Transduct. Res. 28, 15-28.
10. Bootman, M. D., Fearnley, C., Smyrnias, I., Macdonald, F., and Roderick, H. L. (2009). An update on nuclear calcium signalling. J. Cell Sci. 122, 2337-2350.
11. Brkovic, A., Hattenberger, A., Kostenis, E., Klabunde, T., Flohr, S., Kurz, M., et al. (2003). Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay. J. Pharmacol. Exp. Ther. 306, 1200-1209.
12. Carotenuto, A., Grieco, P., Campiglia, P., Novellino, E., and Rovero, P. (2004). Unraveling the active conformation of urotensin II. J. Med. Chem. 47, 1652-1661.
13. Castel, H., Diallo, M., Chatenet, D., Leprince, J., Desrues, L., Schouft, M. T., et al. (2006). Biochemical and functional characterization of high-affinity urotensin II receptors in rat cortical astrocytes.J. Neurochem. 99, 582-595.
14. Chatenet, D., Dubessy, C., Leprince, J., Boularan, C., Carlier, L., Segalas-Milazzo, I., et al. (2004). Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. Peptides25, 1819-1830.
15. Chatenet, D., Nguyen, Q. T., Letourneau, M., Doan, N. D., Dupuis, J., and Fournier, A. (2012a). Discovery of new antagonists aimed at discriminating UII and URP-mediated biological activities: insight into UII and URP receptor activation. Br. J. Pharmacol. doi: 10.111 1/j.1476-5381.2012.02217.x. [Epub ahead of print].
16. Chatenet, D., Nguyen, Q. T., Letourneau, M., Dupuis, J., and Fournier, A. (2012b). Urocontrin, a novel UT receptor ligand with a unique pharmacological profile. Biochem. Pharmacol. 83, 608-615.
17. Christopoulos, A., and Kenakin, T. (2002). G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54, 323-374.
18. Clozel, M., Binkert, C., Birker-Robaczewska, M., Boukhadra, C., Ding, S. S., Fischli, W., et al. (2004). Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System. J. Pharmacol. Exp. Ther. 311,204-212.
19. Clozel, M., Hess, P., Qiu, C., Ding, S. S., and Rey, M. (2006). The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J. Pharmacol. Exp. Ther. 316, 1115-1121.
20. Conlon, J. M., O'Harte, F., Smith, D. D., Tonon, M. C., and Vaudry, H. (1992). Isolation and primary structure of urotensin II from the brain of a tetrapod, the frog Rana ridibunda. Biochem. Biophys. Res. Commun. 188, 578-583.
21. Coulouarn, Y., Lihrmann, I., Jegou, S., Anouar, Y., Tostivint, H., Beauvillain, J. C., et al. (1998). Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneu-rons of the spinal cord. Proc. Natl. Acad. Sci. U.S.A. 95, 15803-15808.
22. Dai, H. Y., Kang, W. Q., Wang, X., Yu, X. J., Li, Z. H., Tang, M. X., et al. (2007). The involvement of transforming growth factor-beta1 secretion in urotensin II-induced collagen synthesis in neonatal cardiac fibroblasts. Regul Pept. 140, 88-93.
23. De Mello, W. C. (2008). Intracellular and extracellular renin have opposite effects on the regulation of heart cell volume. Implications for myocardial ischaemia. J. Renin Angiotensin Aldosterone Syst. 9, 112-118.
24. Diallo, M., Castel, H., Jarry, M., Desrues, L., Lefebvre, T., Leprince, J., et al. (2007). Urotensin II and urotensin II-related peptide regulate normal astrocyte activity. Potential involvement in glioma proliferation. Neuron Glia Biol. 3, S161.
25. Doan, N. D., Nguyen, T. T., Letourneau, M., Turcotte, K., Fournier, A., and Chatenet, D. (2012). Biochemical and pharmacological characterization of nuclear urotensin-II binding sites in rat heart. Br. J. Pharmacol. 166, 243-257.
26. Douglas, S. A., Ashton, D. J., Sauermelch, C. F., Coatney, R. W., Ohlstein, D. H., Ruffolo, M. R., et al. (2000). Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. J. Cardiovasc. Pharmacol. 36, S163-S166.
27. Douglas, S. A., and Ohlstein, E. H. (2000). Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc. Med. 10, 229-237.
28. Dubessy, C., Cartier, D., Lectez, B., Bucharles, C., Chartrel, N., Montero-Hadjadje, M., et al. (2008). Characterization of urotensin II, distribution of urotensin II, urotensin II-related peptide and UT receptor mRNAs in mouse: evidence of urotensin II at the neuromuscular junction. J. Neurochem. 107, 361-374.
29. Duverger, E., Pellerin-Mendes, C., Mayer, R., Roche, A. C., and Monsigny, M. (1995). Nuclear import of glycoconjugates is distinct from the classical NLS pathway. J. Cell Sci. 108(Pt 4), 1325-1332.
30. Eggena, P., Zhu, J. H., Clegg, K., and Barrett, J. D. (1993). Nuclear angiotensin receptors induce transcription of renin and angiotensinogen mRNA. Hypertension 22, 496-501.
31. Elshourbagy, N. A., Douglas, S. A., Shabon, U., Harrison, S., Duddy, G., Sechler, J. L., et al. (2002). Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br. J. Pharmacol. 136, 9-22.
32. Fontes-Sousa, A. P., Pires, A. L., Monteiro-Cardoso, V. F., and Leite-Moreira, A. E (2009). Urotensin II-induced increase in myocardial distensibility is modulated by angiotensin II and endothelin-1. Physiol. Res. 58, 653-660.
33. Gibson, A. (1987). Complex effects of Gillichthys urotensin II on rat aortic strips. Br. J. Pharmacol. 91,205-212.
34. Gibson, A., Bern, H. A., Ginsburg, M., and Botting, J. H. (1984). Neuropeptide-induced contraction and relaxation of the mouse anococ-cygeus muscle. Proc. Natl. Acad. Sci. U.S.A. 81,625-629.
35. Giebing, G., Tolle, M., Jurgensen, J., Eichhorst, J., Furkert, J., Beyermann, M., et al. (2005). Arrestin-independent internal-ization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction. Circ. Res. 97, 707-715.
36. Gobeil, F., Fortier, A., Zhu, T., Bossolasco, M., Leduc, M., Grandbois, M., et al. (2006). G-protein-coupled receptors signalling at the cell nucleus: an emerging paradigm. Can. J. Physiol. Pharmacol. 84, 287-297.
37. Gruson, D., Ginion, A., Decroly, N., Lause, P., Vanoverschelde, J. L., Ketelslegers, J. M., et al. (2010). Urotensin II induction of adult car-diomyocytes hypertrophy involves the Akt/GSK-3beta signaling pathway. Peptides 31, 1326-1333.
38. Guidolin, D., Albertin, G., and Ribatti, D. (2010). Urotensin-II as an angio-genic factor.Peptides31, 1219-1224.
39. Hanyaloglu, A. C., and von Zastrow, M. (2008). Regulation of GPCRs by endocytic membrane trafficking and its potential implications. Annu. Rev. Pharmacol. Toxicol. 48, 537-568.
40. Herold, C. L., Behm, D. J., Buckley, P. T., Foley, J. J., Wixted, W. E., Sarau, H. M., et al. (2003). The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors. Br. J. Pharmacol. 139, 203-207.
41. Hillier, C., Berry, C., Petrie, M. C., O'Dwyer, P. J., Hamilton, C., Brown, A., et al. (2001). Effects of urotensin II in human arteries and veins of varying caliber. Circulation 103, 1378-1381.
42. Hirose, T., Takahashi, K., Mori, N., Nakayama, T., Kikuya, M., Ohkubo, T., et al. (2009). Increased expression of urotensin II, urotensin II-related peptide and urotensin II receptor mRNAs in the cardiovascular organs of hypertensive rats: comparison with endothelin-1. Peptides 30, 1124-1129.
43. Hood, S. G., Watson, A. M., and May, C. N. (2005). Cardiac actions of central but not peripheral urotensin II are prevented by beta-adrenoceptor blockade. Peptides 26, 1248-1256.
44. Jarry, M., Diallo, M., Lecointre, C., Desrues, L., Tokay, T., Chatenet, D., et al. (2010). The vasoactive peptides urotensin II and urotensin II-related peptide regulate astrocyte activity through common and distinct mechanisms: involvement in cell proliferation. Biochem. J. 428, 113-124.
45. Jiang, X., Benovic, J. L., and Wedegaertner, P. B. (2007). Plasma membrane and nuclear localization of G protein coupled receptor kinase 6A. Mol. Biol. Cell 18, 2960-2969.
46. Jong, Y. J., Kumar, V., Kingston, A. E., Romano, C., and O'Malley, K. L. (2005). Functional metabotropic glutamate receptors on nuclei from brain and primary cultured stri-atal neurons. Role of transporters in delivering ligand. J. Biol. Chem. 280, 30469-30480.
47. Jong, Y. J., Kumar, V., and O'Malley, K. L. (2009). Intracellular metabotropic glutamate receptor 5 (mGluR5) activates signaling cascades distinct from cell surface counterparts. J. Biol. Chem. 284, 35827-35838.
48. Kenakin, T. (2005). New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat. Rev. DrugDiscov. 4, 919-927.
49. Kenakin, T. (2008). Functional selectivity in GPCR modulator screening. Comb. Chem. High Throughput Screen. 11,337-343.
50. Kenakin, T. (2011). Functional selectivity and biased receptor signaling. J. Pharmacol. Exp. Ther. 336, 296-302.
51. Kenakin, T., and Miller, L. J. (2010). Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol. Rev. 62, 265-304.
52. Keov, P., Sexton, P. M., and Christopoulos, A. (2011). Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. Neuropharmacology 60, 24-35.
53. Kiefer, P., Acland, P., Pappin, D., Peters, G., and Dickson, C. (1994). Competition between nuclear localization and secretory signals determines the subcellular fate of a single CUG-initiated form of FGF3. EMBO J. 13, 4126-4136.
54. Kohout, T. A., Nicholas, S. L., Perry, S. J., Reinhart, G., Junger, S., and Struthers, R. S. (2004). Differential desensitization, receptor phospho-rylation, beta-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7. J. Biol. Chem. 279,23214-23222.
55. Krum, H., and Kemp, W. (2007). Therapeutic potential of blockade of the urotensin II system in systemic hypertension. Curr. Hypertens. Rep. 9, 53-58.
56. Leach, K., Sexton, P. M., and Christopoulos, A. (2007). Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol. Sci. 28, 382-389.
57. Lee, D. K., Lanca, A. J., Cheng, R., Nguyen, T., Ji, X. D., Gobeil, E Jr., et al. (2004). Agonist-independent nuclear localization of the Apelin, angiotensin AT1, and bradykinin B2 receptors. J. Biol. Chem. 279, 7901-7908.
58. Lee-Kirsch, M. A., Gaudet, F., Cardoso, M. C., and Lindpaintner, K. (1999). Distinct renin isoforms generated by tissue-specific transcription initiation and alternative splicing. Circ. Res. 84, 240-246.
59. Lescot, E., Sopkova-De Oliveira Santos, J., Colloc'h, N., Rodrigo, J., Milazzo-Segalas, I., Bureau, R., et al. (2008). Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and non-peptide antagonists in the binding site and comparison with an antagonist pharmacophore model. Proteins 73, 173-184.
60. Liu, Q., Pong, S. S., Zeng, Z., Zhang, Q., Howard, A. D., Williams, D. L. Jr., et al. (1999). Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem. Biophys. Res. Commun. 266, 174-178.
61. Maguire, J. J., and Davenport, A. P. (2002). Is urotensin-II the new endothelin? Br. J. Pharmacol. 137, 579-588.
62. Maguire, J. J., Kuc, R. E., and Davenport, A. P. (2000). Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br. J. Pharmacol. 131, 441-446.
63. Maguire, J. J., Kuc, R. E., Kleinz, M. J., and Davenport, A. P. (2008). Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: relevance to function. Peptides 29, 735-742.
64. Marchese, A., Heiber, M., Nguyen, T., Heng, H. H., Saldivia, V. R., Cheng, R., et al. (1995). Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. Genomics 29, 335-344.
65. Maryanoff, B. E., and Kinney, W. A. (2010). Urotensin-II receptor modulators as potential drugs. J. Med. Chem. 53, 2695-2708.
66. May, L. T., Leach, K., Sexton, P. M., and Christopoulos, A. (2007). Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47, 1-51.
67. Mori, M., Sugo, T., Abe, M., Shimomura, Y., Kurihara, M., Kitada, C., et al. (1999). Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem. Biophys. Res. Commun. 265, 123-129.
68. Nguyen, T. T., Letourneau, M., Chatenet, D., and Fournier, A. (2012). Presence of urotensin-II receptors at the cell nucleus: specific tissue distribution and hypoxia-induced modulation. Int. J. Biochem. CellBiol. 44, 639-647.
69. Nothacker, H. P., Wang, Z., McNeill, A. M., Saito, Y., Merten, S., O'Dowd, B., et al. (1999). Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat. Cell Biol. 1, 383-385.
70. Ono, T., Kawaguchi, Y., Kudo, M., Kushikata, T., Hashiba, E., Yoshida, H., et al. (2008). Urotensin II evokes neurotransmitter release from rat cerebrocortical slices. Neurosci. Lett. 440, 275-279.
71. Papadopoulos, P., Bousette, N., and Giaid, A. (2008). Urotensin-II and cardiovascular remodeling. Peptides 29, 764-769.
72. Patel, C. B., Noor, N., and Rockman, H. A. (2010). Functional selectivity in adrenergic and angiotensin signaling systems. Mol. Pharmacol. 78, 983-992.
73. Pearson, D., Shively, J. E., Clark, B. R., Geschwind, I. I., Barkley, M., Nishioka, R. S., et al. (1980). Urotensin II: a somatostatin-like peptide in the caudal neurosecre-tory system of fishes. Proc. Natl. Acad. Sci. U.S.A. 77, 5021-5024.
74. Petersen, M. C., Munzenmaier, D. H., and Greene, A. S. (2006). Angiotensin II infusion restores stimulated angiogenesis in the skeletal muscle of rats on a high-salt diet. Am. J. Physiol. Heart Circ. Physiol. 291,H114-H120.
75. Prosser, H. C., Forster, M. E., Richards, A. M., and Pemberton, C. J. (2008). Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury. Peptides 29, 770-777.
76. Proulx, C. D., Holleran, B. J., Lavigne, P., Escher, E., Guillemette, G., and Leduc, R. (2008). Biological properties and functional determinants of the urotensin II receptor. Peptides 29,691-699.
77. Re, R. (1999). The nature of intracrine peptide hormone action. Hypertension 34, 534-538.
78. Re, R. N. (2004). A proposal regarding the biology of memory: participation of intracrine peptide networks. Med. Hypotheses 63, 887-894.
79. Roettger, B. F., Ghanekar, D., Rao, R., Toledo, C., Yingling, J., Pinon, D., et al. (1997). Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol. Pharmacol. 51, 357-362.
80. Rondanino, C., Bousser, M. T., Monsigny, M., and Roche, A. C. (2003). Sugar-dependent nuclear import of glycosylated proteins in living cells. Glycobiology 13, 509-519.
81. Roskoski, R. Jr. (2012). ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol. Res. 66, 105-143.
82. Ross, B., McKendy, K., and Giaid, A. (2010). Role of urotensin II in health and disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R1156-R1172.
83. Shiraishi, Y., Watanabe, T., Suguro, T., Nagashima, M., Kato, R., Hongo, S., et al. (2008). Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice.J. Hypertens. 26, 1955-1965.
84. Silvestre, R. A., Egido, E. M., Hernandez, R., Leprince, J., Chatenet, D., Tollemer, H., et al. (2004). Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas. Eur. J. Endocrinol. 151, 803-809.
85. Song, W., Abdel-Razik, A. E., Lu, W., Ao, Z., Johns, D. G., Douglas, S. A., et al. (2006). Urotensin II and renal function in the rat. Kidney Int. 69, 1360-1368.
86. Sorkin, A., and von Zastrow, M. (2009). Endocytosis and signalling: intertwining molecular networks. Nat. Rev. Mol. CellBiol. 10, 609-622.
87. Spinazzi, R., Albertin, G., Nico, B., Guidolin, D., Di Liddo, R., Rossi, G. P., et al. (2006). Urotensin-II and its receptor (UT-R) are expressed in rat brain endothelial cells, and urotensin-II via UT-R stimulates angiogenesis in vivo and in vitro. Int. J. Mol. Med. 18, 1107-1112.
88. Stirrat, A., Gallagher, M., Douglas, S. A., Ohlstein, E. H., Berry, C., Kirk, A., et al. (2001). Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am. J. Physiol. Heart Circ. Physiol. 280,H925-H928.
89. Sugo, T., Murakami, Y., Shimomura, Y., Harada, M., Abe, M., Ishibashi, Y., et al. (2003). Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem. Biophys. Res. Commun. 310, 860-868.
90. Tadevosyan, A., Vaniotis, G., Allen, B. G., Hebert, T. E., and Nattel, S. (2012). G protein-coupled receptor signalling in the cardiac nuclear membrane: evidence and possible roles in physiological and patho-physiological function. J. Physiol. 590, 1313-1330.
91. Tal, M., Ammar, D. A., Karpuj, M., Krizhanovsky, V., Naim, M., and Thompson, D. A. (1995). A novel putative neuropeptide receptor expressed in neural tissue, including sensory epithelia. Biochem. Biophys. Res. Commun. 209, 752-759.
92. Terrillon, S., and Bouvier, M. (2004). Receptor activity-independent recruitment of betaarrestin2 reveals specific signalling modes. EMBO J. 23,3950-3961.
93. Vaniotis, G., Del Duca, D., Trieu, P., Rohlicek, C. V., Hebert, T. E., and Allen, B. G. (2011). Nuclear beta-adrenergic receptors modulate gene expression in adult rat heart. Cell. Signal. 23, 89-98.
94. Vaudry, H., Do Rego, J. C., Le Mevel, J. C., Chatenet, D., Tostivint, H., Fournier, A., et al. (2010). Urotensin, II, from fish to human. Ann. N.Y. Acad. Sci. 1200, 53-66.
95. Watson, A. M., Lambert, G. W., Smith, K. J., and May, C. N. (2003). Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 42, 373-379.
96. Xu, D., Borges, G. R., Grobe, J. L., Pelham, C. J., Yang, B., and Sigmund, C. D. (2009). Preservation of intracellular renin expression is insufficient to compensate for genetic loss of secreted renin. Hypertension 54, 1240-1247.
97. Yoshimoto, T., Matsushita, M., and Hirata, Y (2004). Role of urotensin II in peripheral tissue as an autocrine/paracrine growth factor. Peptides25, 1775-1781.
98. Zhang, Y G., Li, J., Li, Y G., and Wei, R. H. (2008). Urotensin II induces phenotypic differentiation, migration, and collagen synthesis of adventitial fibroblasts from rat aorta. J. Hypertens. 26, 1119-1126.